PRMT5 and cancer: ~15% of all human cancers lack MTAP (MTAP-) and accumulate by 5–20 folds a metabolic derivative—5′-methylthioadenosine (MTA)—of S-adenosyl-l-methionine (SAM), the cofactor for PRMT5 catalytic activity.